Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cgh.2014.04.014PMID 24768810PMCID PMC4208976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Commentary: dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet

  2014cited by this paper
• The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses

  2014cited by this paper
• A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver.

  2013cited by this paper
• Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients

  2013cited by this paper
• Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

  2013cited by this paper
• The global NAFLD epidemic

  2013cited by this paper
• From NAFLD to NASH to cirrhosis—new insights into disease mechanisms

  2013cited by this paper
• Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.

  2012cited by this paper
• [GRADE guidelines: 7. Rating the quality of evidence - inconsistency].

  2012cited by this paper
• Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cited by this paper
• Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis

  2012cited by this paper
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cited by this paper
• Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

  2011cited by this paper
• A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis

  2011cited by this paper
• GRADE guidelines: 7. Rating the quality of evidence--inconsistency.

  2011cited by this paper
• Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial.

  2011cited by this paper
• Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up

  2010cited by this paper
• Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins.

  2010cited by this paper
• Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study

  2010cited by this paper
• Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

  2010cited by this paper
• Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years

  2010cited by this paper
• Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

  2010cited by this paper
• Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit

  2010cited by this paper
• Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.

  2009cited by this paper
• Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

  2009cited by this paper
• The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients

  2009cited by this paper
• Long-term follow-up of patients with nonalcoholic fatty liver.

  2009cited by this paper
• Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial

  2009cited by this paper
• Thiazolidinediones for the Treatment in NASH: Sustained Benefit After Drug Discontinuation?

  2009cited by this paper
• Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials.

  2008cited by this paper
• Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.

  2008cited by this paper
• Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

  2008cited by this paper
• Nonalcoholic fatty liver disease.

  2008cited by this paper
• The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

  2007cited by this paper
• Long‐term follow‐up of patients with NAFLD and elevated liver enzymes

  2006cited by this paper
• Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C.

  2006cited by this paper
• Histological progression of non‐alcoholic fatty liver disease in Chinese patients

  2005cited by this paper
• The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

  2005cited by this paper
• Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies

  2004cited by this paper
• The natural history of nonalcoholic fatty liver disease: a clinical histopathological study

  2003cited by this paper
• Progression of fibrosis in chronic hepatitis C.

  2003cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?

  2002cited by this paper
• Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

  2001cited by this paper
• Progression of fibrosis in chronic hepatitis C in children

  2001cited by this paper
• Liver fibrosis in overweight patients.

  2000cited by this paper
• Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

  1999cited by this paper
• Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

  1999cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• The natural history of nonalcoholic fatty liver: A follow‐up study

  1995cited by this paper
• Publication bias in clinical research.

  1991cited by this paper
• Nonalcoholic fatty liver disease.

  1986cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper

• HFpEF and MASLD: converging mechanisms and clinical implications.

  2026cites this paper
• Effects of Pemafibrate on Liver Fibrosis in Patients with MASLD and Hypertriglyceridemia: A 2-Year Retrospective Observational Study Using MR Elastography

  2026cites this paper
• MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management-A Narrative Review.

  2026influential citation
• Network Meta-Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution.

  2026cites this paper
• Association Between Nonalcoholic Fatty Liver Disease and the Dietary Index for Gut Microbiota: A Cross‐Sectional Study

  2026cites this paper
• Prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease in Craniopharyngioma Patients Using Non-Invasive Investigations

  2026cites this paper
• Longitudinal Changes in Cardiometabolic Risk Factors are Associated with Changes in Liver Stiffness in Adults with MASLD.

  2026cites this paper
• The role of endoscopic therapies for patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

  2026cites this paper
• Type 2 Diabetes Mellitus and Risk of Advanced Fibrosis in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): The Results of Multi-centre Indian Consortium on MASLD (ICOM-D) Study.

  2026cites this paper
• Can regular physical activity keep metabolic dysfunction-associated steatotic liver disease and its complications away before and/or after transplantation.

  2026cites this paper
• Intermittent fasting ameliorates MAFLD by downregulating Lrg1: insights from bulk RNA sequencing and functional verification.

  2026cites this paper
• Probiotics for managing non-alcoholic fatty liver disease: efficacy and mechanistic insights

  2026cites this paper
• Dual elastography ultrasound for classifying metabolic dysfunction-associated steatotic liver disease: a cross-sectional study within a prospective cohort.

  2026cites this paper
• Investigation of Changes in Liver Fibrosis Scores and Kidney Function in Patients with Diabetic Hepatosteatosis

  2026cites this paper
• Liver Fibrosis and Sudden Cardiac Arrest: A Prospective Cohort Study of 452,454 Individuals.

  2026cites this paper
• Real-world quality of life and healthcare resource utilization in patients with metabolic dysfunction-associated steatohepatitis

  2026cites this paper
• Perspectives of Indian Gastroenterologists and Hepatologists on Nonalcoholic Fatty Liver Disease Diagnosis and Management: Insights From the Nationwide Web-Based Cross-Sectional DRIVE Survey.

  2026cites this paper
• Precision staging of Type 2 diabetes through Hypergraph-Based multimorbidity Profiling: From hepatic disruption to cardiovascular escalation.

  2026cites this paper
• Ameliorative Effects of Black Rice and Purple Sweet Potato Extracts on Methionine–Choline Deficient Diet-induced Non-alcoholic Steatohepatitis (NASH) in Mice

  2026cites this paper
• The African Middle East Association of Gastroenterology (AMAGE) clinical practice guidelines for the diagnosis and management of metabolic dysfunction associated fatty liver disease.

  2026cites this paper
• Progression to Decompensation of Severe Fibrosis Compared to Cirrhosis in MASLD: A Systematic Review and Meta‐Analysis

  2026cites this paper
• Markers Of Insulin Resistance and Their Clinical Implications In Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

  2026cites this paper
• A case of rapid-progressing liver cirrhosis complicated by Werner syndrome

  2025influential citation
• Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma

  2025cites this paper
• Gut microbes mediate the synergistic effects of dietary cholesterol and saturated fat in driving fibrosing MASH

  2025cites this paper
• Association Between Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease: Epidemiological Cross-Sectional Study and Mendelian Randomization Analysis

  2025cites this paper
• A serum exosomal microRNA‐based artificial intelligence diagnostic model for highly accurate detection of hepatocellular carcinoma

  2025cites this paper
• Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• Chronic Nanoplastic Exposure Promotes the Development and Progression of Metabolic Dysfunction‐Associated Steatotic Liver Disease

  2025cites this paper
• Role of mac-2 binding protein glycosylation isomer in predicting fibrosis in patients with metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• Targeting endoplasmic reticulum proteostasis in liver fibrosis: From signaling mechanisms to therapeutic opportunities.

  2025cites this paper
• Hépatopathies stéatosiques dysmétaboliques

  2025cites this paper
• Metabolic-associated steatotic liver disease (MASLD): how I evolved my approach to diagnosis and staging

  2025cites this paper
• Association of metabolic abnormalities and the risk of hepatic fibrosis

  2025cites this paper
• ECM formation and degradation during fibrosis, repair, and regeneration

  2025cites this paper
• Prognostic Value of the TLM3 Biomarker Panel for Early Fibrosis Development in MASLD Within the General Population

  2025cites this paper
• MASLD-related fibrosis, but not MASLD, is associated with left ventricular concentric hypertrophy in patients with type 2 diabetes

  2025cites this paper
• Reducing complications of metabolic dysfunction–associated steatotic liver disease

  2025influential citation
• Metabolic Syndrome and Liver Disease: Re-Appraisal of Screening, Diagnosis, and Treatment Through the Paradigm Shift from NAFLD to MASLD

  2025cites this paper
• Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation

  2025cites this paper
• The Green Path to Liver Health: Herbal Solutions for Non-alcoholic Steatohepatitis.

  2025cites this paper
• Carboxylesterase 2A gene knockout or enzyme inhibition alleviates steatohepatitis in rats by regulating PPARγ and endoplasmic reticulum stress.

  2025cites this paper
• Concordance of vibration-controlled transient elastography and magnetic resonance elastography for fibrosis staging in patients with metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction–associated steatotic liver disease

  2025cites this paper
• Liver cirrhosis in metabolic dysfunction-associated steatohepatitis

  2025cites this paper
• Draft Clinical Guidelines for the Diagnosis and Treatment of Metabolically Associated Fatty Liver Disease in Children (Non-Alcoholic Fatty Liver Disease)

  2025cites this paper
• Associations of serum carotenoids with cardiovascular disease mortality among patients with metabolic dysfunction‐associated steatotic liver disease

  2025cites this paper
• Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model

  2025cites this paper
• Discovery of a Novel Silybin Derivative for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.

  2025cites this paper
• Free-Breathing Hybrid Technique for Simultaneous Morphological and Quantitative Abdominal Imaging at 0.55 T.

  2025cites this paper
• Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• Prevalence of MASLD in People With Diabetes Has Decreased in the US, but Rates of Liver Fibrosis Are Still on the Rise

  2025cites this paper
• Decoding survival in MASLD: the dominant role of metabolic factors

  2025cites this paper
• A Gastroenterologist's Approach to Improving Metabolic Health in MASLD.

  2025cites this paper
• Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• A new insight: crosstalk between neutrophil extracellular traps and the gut-liver axis for nonalcoholic fatty liver disease

  2025cites this paper
• Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs

  2025cites this paper
• Exploring the Role of Probiotics, Prebiotics, and Synbiotics in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease—A Scoping Review

  2025cites this paper
• Obstructive sleep apnea is ralated to metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus

  2025cites this paper
• Telmisartan reverses hepatic steatosis via PCK1 upregulation: A novel PPAR-independent mechanism in experimental models of MASLD

  2025cites this paper
• Cardiovascular implications of MASLD: overview of the evidence

  2025cites this paper
• Fluorofenidone attenuates choline-deficient, l-amino acid-defined, high-fat diet-induced metabolic dysfunction-associated steatohepatitis in mice

  2025cites this paper
• A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta‐Analysis

  2025cites this paper
• Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes.

  2025cites this paper
• Association between excessive screen time and steatotic liver disease in adolescents: Findings from the 2017–2018 National Health and Nutrition Examination Survey

  2025cites this paper
• Validation of the diagnostic accuracy of the acFibroMASH index for at-risk MASH in patients with metabolic dysfunction-associated steatotic liver disease

  2025influential citation
• LEADS - a comprehensive human liver-on-a-chip for non-alcoholic steatohepatitis (NASH) drug testing.

  2025cites this paper
• KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

  2025cites this paper
• Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels

  2025cites this paper
• The significance of metabolism-associated steatotic liver disease and its treatment

  2025cites this paper
• A machine-learning model score predicts advanced fibrosis and cirrhosis in indeterminate FIB-4 patients.

  2025cites this paper
• Prevalence of advanced hepatic fibrosis and individualization of associated risk factors by Bayesian analysis in MASLD patients in French cardio-metabolic health networks

  2025cites this paper
• MOVING DIAGNOSIS OF LIVER FIBROSIS INTO THE COMMUNITY.

  2025cites this paper
• S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion

  2025cites this paper
• At the Crossroads of Health and Disease: Consequences of Fat in the Liver

  2025cites this paper
• Relationship between dietary inflammatory index and metabolic dysfunction associated steatotic liver disease in children

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management

  2025cites this paper
• Untargeted lipidomic analysis of metabolic dysfunction-associated steatohepatitis in women with morbid obesity

  2025cites this paper
• Metabolic dysfunction-associated steatotic liver disease in adults

  2025cites this paper
• S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion

  2025cites this paper
• Roles of extracellular vesicles from different origins in metabolic-associated fatty liver disease: progress and perspectives

  2025influential citation
• A prospective comparison of two ultrasound attenuation imaging modes using different frequencies for assessing hepatic steatosis

  2025cites this paper
• Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group.

  2025cites this paper
• Hallazgos por imagen de las enfermedades hepáticas por depósito

  2025cites this paper
• From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective.

  2025cites this paper
• Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions

  2025cites this paper
• Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease.

  2025cites this paper
• Deletion of H-ferritin in macrophages mitigates the development of steatohepatitis and hepatocellular carcinoma in mice.

  2025cites this paper
• Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis

  2025cites this paper
• Integrated liver-secreted and plasma proteomics identify a predictive model that stratifies MASH.

  2025cites this paper
• Gene-based therapies for steatotic liver disease.

  2025cites this paper
• Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases

  2025cites this paper
• The Heated Race Against MASH: Will the Scope, Scalpel, or Medication Prevail?

  2025cites this paper
• Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study

  2025cites this paper
• The Roles of T Cells in the Development of Metabolic Dysfunction‐Associated Steatohepatitis

  2025cites this paper
• Cultural and Molecular Factors Predisposed to Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.

  2025cites this paper
• Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.

  2025cites this paper
• Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors

  2025cites this paper